SCHEMBL3092907

SCHEMBL3092907

CC(C)N(C(=O)C(CC1CC1)C(=O)NS(=O)(=O)c1ccc(OC(F)(F)F)cc1)c1ccc(F)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
LTC4S Q16873 1/20 0.41
PTGIR P43119 1/20 0.41
HTR7 P34969 1/20 0.39
EGFR P00533 1/20 0.37
ERBB2 P04626 1/20 0.37
CXCR3 P49682 1/20 0.37
NPC1 O15118 1/20 0.36
DPP4 P27487 6/20 0.36
DPP7 Q9UHL4 4/20 0.36
KCNH2 Q12809 1/20 0.36
DPP8 Q6V1X1 1/20 0.36
DPP9 Q86TI2 1/20 0.36
NR1H4 Q96RI1 1/20 0.36
HDAC8 Q9BY41 3/20 0.36
HDAC3 O15379 2/20 0.36
HDAC4 P56524 2/20 0.36
HDAC1 Q13547 2/20 0.36
HDAC7 Q8WUI4 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3083883 0.90 EGFR (0.48) USP30LTC4SHTR7EGFRERBB2
SCHEMBL3087959 0.88 EGFR (0.45) USP30L3MBTL1EGFRERBB2
SCHEMBL3092116 0.87 TARS1 (0.48)
SCHEMBL3089589 0.87 USP30 (0.42) USP30NR1H4HDAC8
SCHEMBL3092840 0.87 EGFR (0.44) USP30L3MBTL1LTC4SPTGIREGFR
SCHEMBL3097794 0.85 BCL2L1 (0.41) USP30
SCHEMBL3096770 0.85 EGFR (0.39) USP30EGFRERBB2
SCHEMBL3091920 0.83 CCR5 (0.39) USP30
SCHEMBL3092864 0.83 LARS1 (0.48) HTR7HDAC8HDAC3HDAC4HDAC1
SCHEMBL3097806 0.82 FBP1 (0.36) USP30LTC4SEGFRERBB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2172450-B9 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2014-10-08 EP disclosed
EP-2172450-B1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2013-10-16 EP disclosed
US-8461209-B2 Malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-11 US disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 US disclosed
EP-2172450-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF Mitsubishi Tanabe Pharma Corporation (JP) 2010-04-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF REN, AGTR2, AGTR1 USP30 1341/4885L3MBTL1 4273/4885LTC4S 2163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.